$RRBI

Red River Bancshares, Inc. Reports Second Quarter 2026 Financial Results

RED RIVER BANCSHARES INC (RRBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Red River Bancshares, Inc. Reports Second Quarter 2026 Financial Results ALEXANDRIA, Louisiana, July 30, 2026 (GLOBE NEWSWIRE) -- Red River Bancshares, Inc. (the “Company”) (Nasdaq: RRBI), the holding company for Red River Bank (the “Bank”), ann

Original reporting
Published Jul 30, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RRBI
Neutral
medium confidence
Mentioned
$RRBI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RRBINeutralMed
01

Why it matters

Traders can reassess near-term earnings power based on NIM expansion (10 bps), deposit outflows (-1.4% QoQ), and modest credit improvement (NPA down 38.3% to 0.08% of assets). Management also flags expectations for higher loan growth in 2H 2026.

02

Market read

The filing is a primary earnings datapoint for RRBI, with specific margin, deposit, and credit metrics that can drive small-cap bank positioning.

03

What to watch

The deposit drop is attributed to seasonal tax outflows and lawyer trust account timing, which may reverse, but investors may still discount near-term funding stability.

Relevance 7/10Novelty 6/10Timing: filed pre-market today (8:45 a.m. ET) with Q2 2026 results

Background

SEC 8-K Item 2.02 with Exhibit 99.1 reporting unaudited Q2 2026 financial results for Red River Bancshares, Inc.

Company-level read

Ticker impact

$RRBINeutralMedium confidence
Context

RRBI reported Q2 2026 net income of $11.8M and EPS $1.78, with NIM FTE rising 10 bps to 3.61% and deposits down $40.9M QoQ.

Expected impact

Near-term trading likely hinges on whether investors view NIM expansion as offsetting deposit softness and higher operating expenses.

Evidence & confidence

The filing provides concrete quarterly datapoints (income, NIM, deposits, NPA) and a management outlook for higher loan growth in 2H, but it does not include guidance ranges or a major balance-sheet inflection.

Market effects

Regional bank read-through: NIM expansion and deposit volatility are key themes for small-cap bank sentiment.

Louisiana-focused franchise updates (relocations and expansion) may affect local deposit/loan growth expectations.

Limited direct global linkage; primarily US rates and regional credit conditions.

Counterpoint

Deposit declines and higher operating expenses could dominate the narrative even with NIM expansion, making the quarter look less resilient than the margin headline suggests.

Key entities

  • Red River Bancshares, Inc.

    Nasdaq-listed holding company for Red River Bank; reported Q2 2026 results and provided operational updates.

  • Red River Bank

    Operating bank within the holding company; board changes and expansion projects referenced.

  • State Street SPDR S&P Regional Banking ETF (KRE)

    RRBI was added to KRE during the June 2026 quarterly rebalance.

Related articles

$LPLHighAI 8/10

LG Display (LPL) Q3 2026 Earnings Call Transcript

LG Display (LPL) reported Q3 2026 net income of KRW 755.6 billion, with operating profit margin at 4% and EBITDA at 19%. Area shipment grew 4% Q-o-Q to 3.7 million square meters, and ASP rose 16% to $1,250. OLED products accounted for 67% of revenue. The company expects Q4 shipment growth of around 10% but modest ASP increases due to market uncertainties. LG Display is focusing on OLED technology, including its next-gen FLiPP technology, to maintain competitiveness and profitability.

$RDYMed

Dr. Reddy’s Q2FY27 slides: base growth masks lenalidomide drag

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenues of ₹8,671 crores, down 1.5% YoY but up 7% sequentially. EBITDA margin was 20.6%, with profit after tax at ₹925 crores. North America sales declined 23% YoY due to lenalidomide, but other regions showed growth. The company announced strategic partnerships and product developments, including a dengue vaccine and biosimilars. Shares rose 0.45% to $13.29 post-results.